Jonathan Cebon

44.9k total citations · 4 hit papers
278 papers, 13.6k citations indexed

About

Jonathan Cebon is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Jonathan Cebon has authored 278 papers receiving a total of 13.6k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Oncology, 141 papers in Immunology and 116 papers in Molecular Biology. Recurrent topics in Jonathan Cebon's work include Immunotherapy and Immune Responses (115 papers), CAR-T cell therapy research (55 papers) and Cancer Immunotherapy and Biomarkers (43 papers). Jonathan Cebon is often cited by papers focused on Immunotherapy and Immune Responses (115 papers), CAR-T cell therapy research (55 papers) and Cancer Immunotherapy and Biomarkers (43 papers). Jonathan Cebon collaborates with scholars based in Australia, United States and Belgium. Jonathan Cebon's co-authors include Ian D. Davis, Eugene Maraskovsky, Andreas Behren, Graham J. Lieschke, Weisan Chen, Thomas Luft, George Morstyn, Tracey Toy, Darryl Maher and Georgina V. Long and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Jonathan Cebon

275 papers receiving 13.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

2017 1.1k citations Jonathan Cebon et al. profile →
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

2000 936 citations Jonathan Cebon et al. profile →
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.

1994 678 citations Jonathan Cebon et al. profile →
A gut microbial signature for combination immune checkpoint blockade across cancer types

2024 67 citations Ashray Gunjur, Oliver Klein et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jonathan Cebon	6.6k	6.3k	4.7k	1.4k	1.2k	278	13.6k
Wyndham H. Wilson	4.8k 0.7×	9.0k 1.4×	4.0k 0.8×	1.2k 0.9×	1.2k 1.0×	329	17.6k
Vassiliki A. Boussiotis	9.5k 1.4×	5.5k 0.9×	3.8k 0.8×	744 0.5×	883 0.7×	182	15.6k
Crystal L. Mackall	8.5k 1.3×	7.1k 1.1×	3.2k 0.7×	1.7k 1.3×	935 0.8×	168	16.1k
Peter Brossart	6.6k 1.0×	4.5k 0.7×	4.9k 1.0×	628 0.5×	1.0k 0.8×	289	12.3k
Taha Merghoub	6.3k 1.0×	6.9k 1.1×	4.3k 0.9×	1.2k 0.9×	1.2k 1.0×	210	12.5k
Ivan D. Horak	5.7k 0.9×	3.9k 0.6×	4.8k 1.0×	1.4k 1.0×	880 0.7×	205	14.0k
Hiroshi Shiku	6.6k 1.0×	4.4k 0.7×	6.7k 1.4×	1.1k 0.8×	1.2k 1.0×	535	16.3k
Ena Wang	7.2k 1.1×	6.3k 1.0×	5.4k 1.1×	1.4k 1.0×	949 0.8×	260	14.2k
Barbara Seliger	8.1k 1.2×	6.3k 1.0×	5.3k 1.1×	896 0.7×	1.4k 1.2×	362	15.2k
Giorgio Cattoretti	4.9k 0.7×	4.2k 0.7×	6.6k 1.4×	1.2k 0.9×	845 0.7×	183	16.3k

Countries citing papers authored by Jonathan Cebon

Since Specialization

Citations

This map shows the geographic impact of Jonathan Cebon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Cebon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Cebon more than expected).

Fields of papers citing papers by Jonathan Cebon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Cebon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Cebon. The network helps show where Jonathan Cebon may publish in the future.

Co-authorship network of co-authors of Jonathan Cebon

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Cebon. A scholar is included among the top collaborators of Jonathan Cebon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Cebon. Jonathan Cebon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Balasubramanian, Akhila, Jodie Palmer, Michael Christie, et al.. (2025). Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial. Clinical Cancer Research. 31(22). 4644–4654.

Klein, Oliver, Matteo S. Carlino, Craig Underhill, et al.. (2024). 713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial. Annals of Oncology. 35. S546–S547. 5 indexed citations

Duarte, Jessica Da Gama, Katherine Woods, Candani Tutuka, et al.. (2021). Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses. Cancers. 13(8). 1805–1805. 1 indexed citations

Klein, Oliver, Damien Kee, Ben Markman, et al.. (2020). Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. Clinical Cancer Research. 26(17). 4454–4459. 116 indexed citations

Wang, Jing, Alain Wuethrich, Abu Ali Ibn Sina, et al.. (2020). Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma. Science Advances. 6(9). eaax3223–eaax3223. 131 indexed citations

Gray, Elin S., Michelle R. Pereira, Leslie Calapre, et al.. (2019). Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. Journal of Molecular Diagnostics. 21(3). 418–426. 18 indexed citations

Lee, Erinna F., Tiffany J. Harris, Sharon Tran, et al.. (2019). BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death and Disease. 10(5). 342–342. 142 indexed citations

Cebon, Jonathan. (2018). Perspective: cancer vaccines in the era of immune checkpoint blockade. Mammalian Genome. 29(11-12). 703–713. 12 indexed citations

Yao, Jun, Otávia L. Caballero, Ying Huang, et al.. (2016). Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity. Cancer Immunology Research. 4(6). 552–561. 49 indexed citations

10.

Andrews, Miles C., Natalie Turner, Andrew W. Roberts, et al.. (2015). Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. Clinical Cancer Research. 21(23). 5222–5234. 3 indexed citations

11.

Robson, Neil C., Laura Hidalgo, Heng Wei, et al.. (2014). Optimal Effector Functions in Human Natural Killer Cells Rely upon Autocrine Bone Morphogenetic Protein Signaling. Cancer Research. 74(18). 5019–5031. 21 indexed citations

12.

Vella, Laura J., Anupama Pasam, Nektaria Dimopoulos, et al.. (2014). MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells. Cancer Immunology Research. 2(4). 351–360. 116 indexed citations

13.

Woods, Katherine & Jonathan Cebon. (2013). Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma. Clinical Cancer Research. 19(15). 4021–4023. 12 indexed citations

14.

Mar, Victoria, Stephen Q. Wong, Jason Li, et al.. (2013). BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. Clinical Cancer Research. 19(17). 4589–4598. 100 indexed citations

15.

Davis, Ian D., Richard Kefford, Michael Millward, et al.. (2009). Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial. Clinical Cancer Research. 15(6). 2123–2129. 120 indexed citations

16.

John, Thomas, Michael A. Black, Tumi Toro, et al.. (2008). Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma. Clinical Cancer Research. 14(16). 5173–5180. 44 indexed citations

17.

Ebert, Lisa M., Bee Shin Tan, Judy Browning, et al.. (2008). The Regulatory T Cell–Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells. Cancer Research. 68(8). 3001–3009. 152 indexed citations

18.

Davis, Ian D., Birte K. Skrumsager, Jonathan Cebon, et al.. (2007). An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma. Clinical Cancer Research. 13(12). 3630–3636. 132 indexed citations

19.

Schnurr, Max, Tracey Toy, Amanda Shin, et al.. (2003). Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood. 103(4). 1391–1397. 150 indexed citations

20.

Dempsey, Peter J., Judith E. Layton, Ulrich Dührsen, et al.. (1990). Monoclonal Antibodies that Recognize Human Granulocyte-Macrophage Colony-Stimulating Factor and Neutralize Its Bioactivity In Vitro. Hybridoma. 9(6). 545–558. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact